A combination of nivolumab, trastuzumab and chemotherapy prolonged PFS and OS among patients with previously untreated, metastatic ERBB2-positive esophagogastric cancer, according to study results published in JAMA Oncology.
Researchers concluded that the chemotherapy backbone is needed and should not be replaced by ipilimumab in this patient population.
“We sought to evaluate the combination of checkpoint inhibitors and ERBB2-targeted treatment either with dual checkpoint blockade or chemotherapy to improve first-line treatment of ERBB2-positive esophagogastric adenocarcinoma,”